Companies
Marken
A UPS Healthcare company operating across 43 countries with around 1,406 staff and roughly GBP 168.9 million in revenue, headquartered in Durham, North Carolina.
- Country
- United States
GDP
IATA CEIV Pharma
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| cleanroom-facilities | ✓ | ✓ | — | ✓ |
| logistics-supply-chain | ✓ | ✓ | ✓ | ✓ |
| regulatory-legal | ✓ | ✓ | — | ✓ |
Regulatorsfdaemanmpausda-aphis
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | Marken is a subsidiary of United Parcel Service (UPS), and as such does not report separate independent funding rounds. | marken.com |
| Capacity | Operates 58 worldwide facilities, including 100,000+ square feet of GMP-compliant depot operations added in specific locations in 2021. medium confidence | prnewswire.com |
| Certification | Locations maintain ISO 27001:2022, ISO 14001:2015, ISO 13485, and ISO 9001 certifications. | marken-logistics.files.svdcdn.com · marken.com |
| Regulatory approval | Operations are GMP- and GDP-compliant. | marken.com · ncbiotech.org · prnewswire.com |
| Production site | Operates a global network with 58+ facilities/locations worldwide. | ncbiotech.org · prnewswire.com |
| Revenue | Reported revenue for Marken Limited was GBP 339 million in 2024; other sources estimate annual revenue in the range of GBP 168.9 million to over USD 900 million depending on reporting scope. medium confidence | pomanda.com |
Independent sources: ncbiotech.org · pomanda.com · prnewswire.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Bio import/export customs brokerage | regulatory-legal | Low | → |
| Biospecimen logistics for clinical trials | logistics-supply-chain | Low | → |
| Cold chain for cell & gene therapies | cleanroom-facilities | Low | → |
| Hazardous biomaterials transport (IATA Class 6.2) | logistics-supply-chain | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.